<VariationArchive VariationID="433884" VariationName="NM_000251.3(MSH2):c.1534_1543del (p.Lys512fs)" VariationType="Deletion" Accession="VCV000433884" Version="2" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-23" DateCreated="2017-08-28" MostRecentSubmission="2017-08-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="427147" VariationID="433884">
      <GeneList>
        <Gene Symbol="MSH2" FullName="mutS homolog 2" GeneID="4436" HGNC_ID="HGNC:7325" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>2p21-16.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="47403067" stop="47709830" display_start="47403067" display_stop="47709830" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="47630205" stop="47710366" display_start="47630205" display_stop="47710366" Strand="+" />
          </Location>
          <OMIM>609309</OMIM>
          <Haploinsufficiency last_evaluated="2021-10-13" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=MSH2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-10-13" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=MSH2">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000251.3(MSH2):c.1534_1543del (p.Lys512fs)</Name>
      <CanonicalSPDI>NC_000002.12:47466676:GATTAAACTGGATT:GATT</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>2p21</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="47466677" stop="47466686" display_start="47466677" display_stop="47466686" variantLength="10" positionVCF="47466676" referenceAlleleVCF="AGATTAAACTG" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="47693816" stop="47693825" display_start="47693816" display_stop="47693825" variantLength="10" positionVCF="47693815" referenceAlleleVCF="AGATTAAACTG" alternateAlleleVCF="A" />
      </Location>
      <ProteinChange>K512fs</ProteinChange>
      <ProteinChange>K446fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000251.2" sequenceAccession="NM_000251" sequenceVersion="2" change="c.1534_1543delAAACTGGATT">
            <Expression>NM_000251.2:c.1534_1543delAAACTGGATT</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.11" sequenceAccession="NC_000002" sequenceVersion="11" change="g.47693820_47693829del" Assembly="GRCh37">
            <Expression>NC_000002.11:g.47693820_47693829del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.12" sequenceAccession="NC_000002" sequenceVersion="12" change="g.47466681_47466690del" Assembly="GRCh38">
            <Expression>NC_000002.12:g.47466681_47466690del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007110.2" sequenceAccession="NG_007110" sequenceVersion="2" change="g.68558_68567del">
            <Expression>NG_007110.2:g.68558_68567del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000251.3" sequenceAccession="NM_000251" sequenceVersion="3" change="c.1534_1543del" MANESelect="true">
            <Expression>NM_000251.3:c.1534_1543del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000242.1" sequenceAccession="NP_000242" sequenceVersion="1" change="p.Lys512fs">
            <Expression>NP_000242.1:p.Lys512fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001258281.1" sequenceAccession="NM_001258281" sequenceVersion="1" change="c.1336_1345del">
            <Expression>NM_001258281.1:c.1336_1345del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001245210.1" sequenceAccession="NP_001245210" sequenceVersion="1" change="p.Lys446fs">
            <Expression>NP_001245210.1:p.Lys446fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_218" sequenceAccession="LRG_218">
            <Expression>LRG_218:g.68558_68567del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA645372539" DB="ClinGen" />
        <XRef Type="rs" ID="1553366522" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000251.3(MSH2):c.1534_1543del (p.Lys512fs) AND Carcinoma of colon" Accession="RCV000501065" Version="2">
        <ClassifiedConditionList TraitSetID="1735">
          <ClassifiedCondition DB="MedGen" ID="C0699790">Carcinoma of colon</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2017-08-28" MostRecentSubmission="2017-08-28">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="1735" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="10229" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Colon carcinoma</ElementValue>
                <XRef ID="MONDO:0002032" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Carcinoma of colon</ElementValue>
                <XRef ID="269533000" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Colonic carcinoma</ElementValue>
                <XRef ID="MONDO:0002032" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CRC</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, ovary, stomach, small bowel, urinary tract, biliary tract, brain (usually glioblastoma), skin (sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas), pancreas, and prostate. Cancer risks and age of onset vary depending on the associated gene. Several other cancer types have been reported to occur in individuals with Lynch syndrome (e.g., breast, sarcomas, adrenocortical carcinoma). However, the data are not sufficient to demonstrate that the risk of developing these cancers is increased in individuals with Lynch syndrome.</Attribute>
                <XRef ID="NBK1211" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301390</ID>
                <ID Source="BookShelf">NBK1211</ID>
              </Citation>
              <Citation Type="general" Abbrev="EGAPP, 2009">
                <ID Source="pmc">2743612</ID>
              </Citation>
              <Citation Type="general" Abbrev="EGAPP, 2009">
                <ID Source="pmc">2743610</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="AMA/NCHPEG, 2012">
                <URL>http://www.nchpeg.org/documents/crc/11-0456%20Fact%20sheets%20(MSI%20and%20IHC%20testing).pdf</URL>
              </Citation>
              <Citation Type="general" Abbrev="NACB, 2008">
                <ID Source="PubMed">19042984</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="AHRQ, 2013">
                <URL>https://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id90TA.pdf</URL>
                <CitationText>Technology Assessment on Genetic Testing or Molecular Pathology Testing of Cancers with Unknown Primary Site to Determine Origin (ARCHIVED)</CitationText>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Imperiale et al., 2014">
                <ID Source="PubMed">25006736</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2006">
                <ID Source="PubMed">17060676</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="NCCN, 2011">
                <ID Source="PubMed">22138009</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACP MPDG, 2014">
                <ID Source="PubMed">24996433</ID>
              </Citation>
              <Citation Type="general" Abbrev="SEAP/SEOM, 2012">
                <ID Source="PubMed">22855150</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESMO, 2012">
                <ID Source="PubMed">23012255</ID>
              </Citation>
              <Citation Type="general" Abbrev="SEAP/SEOM, 2015">
                <ID Source="PubMed">25373533</ID>
              </Citation>
              <Citation Type="general" Abbrev="EGTM, 2014">
                <ID Source="PubMed">23852704</ID>
              </Citation>
              <Citation Type="general" Abbrev="EGAPP, 2013">
                <ID Source="PubMed">23429431</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer, 2024</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="EHTG/ESCP, 2021">
                <ID Source="PubMed">34043773</ID>
              </Citation>
              <Citation Type="general" Abbrev="SEAP/SEOM, 2020">
                <ID Source="PubMed">32418154</ID>
                <ID Source="pmc">7505870</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Colon-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics Family History ACT Sheet, Colon Cancer (Asymptomatic), 2012</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2021">
                <URL>https://www.nice.org.uk/guidance/ng151</URL>
                <CitationText>UK NICE Guideline NG151, Colorectal cancer, 2021</CitationText>
              </Citation>
              <XRef ID="C0699790" DB="MedGen" />
              <XRef ID="MONDO:0002032" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1148949" SubmissionDate="2021-03-31" DateLastUpdated="2017-08-28" DateCreated="2017-08-28">
        <ClinVarSubmissionID localKey="chr2:47693814-47693825:992b8596462bbc626b5e7894bdf17fe9-COLON" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000592505" DateUpdated="2017-08-28" DateCreated="2017-08-28" Type="SCV" Version="2" SubmitterName="Department of Pathology and Laboratory Medicine, Sinai Health System" OrgID="506152" OrganizationCategory="laboratory" OrgAbbreviation="PLM-SHS" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="506759" SubmitterName="Franklin by Genoox" Type="secondary" OrganizationCategory="other" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The MSH2 p.Lys512Profs*11 variant was not identified in the literature nor was it identified in the dbSNP or UMD-LSDB databases. The variant was identified in ClinVar, although our laboratory was the only submitter. The variant was not identified in the following control databases: the Exome Aggregation Consortium (August 8th 2016) or the Genome Aggregation Database (Feb 27, 2017). The c.1534_1543del variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 512 and leads to a premature stop codon at position 522. This alteration is then predicted to result in a truncated or absent protein and loss of function. Loss of function variants of the MSH2 gene are an established mechanism of disease in Lynch syndrome and is the type of variant expected to cause the disorder. In summary, based on the above information, this variant meets our laboratoryâ€šÃ„Ã´s criteria to be classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MSH2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="2" alternateAllele="A" referenceAllele="AGATTAAACTG" start="47693815" stop="47693825" variantLength="11" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0002032" />
          </Trait>
        </TraitSet>
        <StudyName>The Canadian Open Genetics Repository (COGR)</StudyName>
        <SubmissionNameList>
          <SubmissionName>SUB9371647</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1148949" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0002032" MappingRef="MONDO">
        <MedGen CUI="C0699790" Name="Carcinoma of colon" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

